United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Report 2017

United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Report 2017

1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Overview

1.1 Product Overview and Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

1.2 Classification of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

1.2.1 Preface

1.2.2 Eluxadoline

1.2.3 Alosetron

1.2.4 Rifaximin

1.2.5 Loperamide

1.2.6 Diphenoxylate + Atropine

1.2.7 Dicyclomine and Hyoscyamine

1.3 Application of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

1.3.1 Hospitals

1.3.2 Clinics

1.3.3 Others

1.4 United States Market Size Sales (Volume) and Revenue (Value) of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs (2012-2022)

1.4.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2012-2022)

1.4.2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2012-2022)

2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competition by Manufacturers

2.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share of Key Manufacturers (2015 and 2016)

2.2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Share by Manufactures (2015 and 2016)

2.3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufactures (2015 and 2016)

2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends

2.4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate

2.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share of Top 3 and Top 5 Manufacturers

2.4.3 Mergers & Acquisitions, Expansion

3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Volume) and Revenue (Value) by States (2012-2017)

3.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by States (2012-2017)

3.2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by States (2012-2017)

3.3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by States (2012-2017)

4 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Volume) and Revenue (Value) by Type (2012-2017)

4.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Type (2012-2017)

4.2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2012-2017)

4.3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2012-2017)

4.4 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Type (2012-2017)

5 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Volume) by Application (2012-2017)

5.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Application (2012-2017)

5.2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

6 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Profiles/Analysis

6.1 Astellas Pharmaceuticals

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification

6.1.2.1 Preface

6.1.2.2 Eluxadoline

6.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Actavis

6.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification

6.2.2.1 Preface

6.2.2.2 Eluxadoline

6.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 Pfizer

6.3.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification

6.3.2.1 Preface

6.3.2.2 Eluxadoline

6.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 GlaxoSmithKline

6.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification

6.4.2.1 Preface

6.4.2.2 Eluxadoline

6.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 Salix Pharmaceuticals Ltd

6.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification

6.5.2.1 Preface

6.5.2.2 Eluxadoline

6.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 AstraZenenca

6.6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type, Application and Specification

6.6.2.1 Preface

6.6.2.2 Eluxadoline

6.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis

7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Manufacturers in 2015

8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

11 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2017-2022)

11.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue Forecast (2017-2022)

11.2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2017-2022)

11.3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Application (2017-2022)

11.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast (2017-2022)

12 Research Findings and Conclusion

13 Appendix

Methodology

Analyst Introduction

Data Source

Figure Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Table Classification of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Figure United States Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type in 2015

Figure Preface Picture

Figure Eluxadoline Picture

Figure Alosetron Picture

Figure Rifaximin Picture

Figure Loperamide Picture

Figure Diphenoxylate + Atropine Picture

Figure Dicyclomine and Hyoscyamine Picture

Table Application of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Figure United States Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application in 2015

Figure Hospitals Examples

Figure Clinics Examples

Figure Others Examples

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2012-2022)

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2012-2022)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales of Key Manufacturers (2015 and 2016)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers (2015 and 2016)

Figure 2015 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers

Figure 2016 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2015 and 2016)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015 and 2016)

Table 2015 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers

Table 2016 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers

Table United States Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price of Key Manufacturers (2015 and 2016)

Figure United States Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price of Key Manufacturers in 2015

Figure Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share of Top 3 Manufacturers

Figure Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share of Top 5 Manufacturers

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by States (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by States (2012-2017)

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by States in 2015

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by States (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by States (2012-2017)

Figure Revenue Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by States (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by States (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2012-2017)

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2015

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2012-2017)

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Type (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2012-2017)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2012-2017)

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2015

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Application (2012-2017)

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Application (2012-2017)

Table Astellas Pharmaceuticals Basic Information List

Table Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Figure Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share (2012-2017)

Table Actavis Basic Information List

Table Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share (2012-2017)

Table Pfizer Basic Information List

Table Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share (2012-2017)

Table GlaxoSmithKline Basic Information List

Table GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share (2012-2017)

Table Salix Pharmaceuticals Ltd Basic Information List

Table Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share (2012-2017)

Table AstraZenenca Basic Information List

Table AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

Table AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Figure Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Figure Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis

Table Raw Materials Sources of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Manufacturers in 2015

Table Major Buyers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Table Distributors/Traders List

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production and Growth Rate Forecast (2017-2022)

Figure United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate Forecast (2017-2022)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Forecast by Type (2017-2022)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Application (2017-2022)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by States (2017-2022)

Table United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share Forecast by States (2017-2022)